United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 50mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

popular pharmaceuticals ltd. - safinamide - tablet - 50 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

popular pharmaceuticals ltd. - safinamide - tablet - 100 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. - safinamide - tablet - 50 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. - safinamide - tablet - 100 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: hi-eisai pharmaceutical, inc.; distributor: zuellig pharma corporation - safinamide (as mesilate) - film-coated tablet - 50mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eisai (malaysia) sdn bhd (18039-d) - safinamide mesylate -

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - safinamide mesilate - white tablet, diameter: approx. 7.1 mm, thickness: approx. 3.5 mm

European Union - English - EMA (European Medicines Agency)

bial - portela cª, s.a. - opicapone - parkinson disease - anti-parkinson drugs - ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.